Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas

Paola Ghione, Kurt S. Bantilan, Erel Joffe, M. Lia Palomba, Ariela Noy, Philip Caron, Paul Hamlin, Anita Kumar, Matthew Matasar, Colette Owens, Alison Moskowitz, Lorenzo Falchi, David Straus, Steven Horwitz, Gilles Salles, Ahmet Dogan, Andrew D. Zelenetz

Blood Neoplasia (2024) 1 (4): 100031.

https://doi.org/10.1016/j.bneo.2024.100031

Published: 2024

Journal Articles

BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis

Wangisa Dunuwille, William C. Wilson, Hassan Bjeije, Nancy Issa, Wentao Han, Tyler M. Parsons, Andrew L. Young, Infencia Xavier Raj, Aishwarya Krishnan, Tarang Gaur, Eunice S. Wang, Andrew P. Weng, Matthew C. Stubbs, Hamza Celik, Amanda F. Cashen, John R. Edwards, Grant A. Challen

Blood Neoplasia (2024) 1 (4): 100040.

https://doi.org/10.1016/j.bneo.2024.100040

Published: 2024

Includes: Supplemental data

Journal Articles

COVID-19 vaccination in patients with classic and variant hairy cell leukemia

Robert J. Kreitman, Lacey James, Julie Feurtado, Holly Eager, Olena Sierra Ortiz, Mory Gould, Isaac Shpilman, Hong Zhou, Peter D. Burbelo, Jeffrey I. Cohen, Hao-Wei Wang, Constance M. Yuan, Evgeny Arons

Blood Neoplasia (2024) 1 (4): 100035.

https://doi.org/10.1016/j.bneo.2024.100035

Published: 2024

Journal Articles

Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy

Blood Neoplasia (2024) 1 (4): 100044.

https://doi.org/10.1016/j.bneo.2024.100044

Published: 2024

Includes: Supplemental data

Journal Articles

Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma

Eunice Lai, Yu Yang Soon, Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Cinnie Yentia Soekojo, Melissa Ooi, Wee Joo Chng, Sanjay de Mel

Blood Neoplasia (2024) 1 (4): 100042.

https://doi.org/10.1016/j.bneo.2024.100042

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical and pathological features of pediatric peripheral T-cell lymphoma after solid organ transplantation

Jinjun Cheng, Rachel Mariani, Jyotinder Nain Punia, Marimar de la Cruz Bonilla, Pichayut Nithagon, Metin Ozdemirli, Wen Shuai, Larry Wang, Oussama Abla, Shunyou Gong

Blood Neoplasia (2024) 1 (4): 100039.

https://doi.org/10.1016/j.bneo.2024.100039

Published: 2024

Includes: Supplemental data

Journal Articles

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Hiroki Kobayashi, Ryota Chijimatsu, Yusuke Naoi, Yoshihiro Otani, Ryo Mizuta, Kentaro Fujii, Joji Ishida, Hiroyuki Murakami, Hideki Ujiie, Kazuhiro Ikeuchi, Tomohiro Urata, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Nobuharu Fujii, Ken-ichi Matsuoka, Yasuharu Sato, Maeda Yoshinobu, Daisuke Ennishi

Blood Neoplasia 100058.

https://doi.org/10.1016/j.bneo.2024.100058

Published: 2024

Includes: Supplemental data

Journal Articles

JAK1/2 Inhibitor Ruxolitinib for the Treatment of Systemic Chronic Active Epstein-Barr Virus Disease: A Phase II Study

Yu Uemura, Masahide Yamamoto, Masataka Ishimura, Hirokazu Kanegane, Akihisa Sawada, Akihiro Hirakawa, Ken-Ichi Imadome, Mayumi Yoshimori, Masashi Nagata, Kouhei Yamamoto, Norio Shimizu, Ryuji Koike, Ayako Arai

Blood Neoplasia 100053.

https://doi.org/10.1016/j.bneo.2024.100053

Published: 2024

Includes: Supplemental data

Journal Articles

T-cell lymphoblastic lymphoma compared with T-cell acute lymphoblastic leukemia: similar subtypes and different fusions

Emma Kroeze, Michelle M. Kleisman, Rico Hagelaar, Reno S. Bladergroen, Lennart A. Kester, Marijn A. Scheijde-Vermeulen, Freerk van Dijk, Jules P. P. Meijerink, Roland P. Kuiper, Jan L. C. Loeffen

Blood Neoplasia (2024) 1 (3): 100029.

https://doi.org/10.1016/j.bneo.2024.100029

Published: 2024

Includes: Supplemental data

Journal Articles

Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice

Natalia Timofeeva, Nitin Jain, Varsha Gandhi

Blood Neoplasia (2024) 1 (3): 100034.

https://doi.org/10.1016/j.bneo.2024.100034

Published: 2024

Journal Articles

Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study

Blood Neoplasia (2024) 1 (3): 100033.

https://doi.org/10.1016/j.bneo.2024.100033

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation

Nilanjan Ghosh, Ruibin Wang, Zaina P. Qureshi, Zhijie Ding, Marie-Hélène Lafeuille, Bruno Emond, Bronwyn Moore, Jinghua He, Alex Bokun, Heena Mavani, Kerry A. Rogers

Blood Neoplasia (2024) 1 (3): 100022.

https://doi.org/10.1016/j.bneo.2024.100022

Published: 2024

Includes: Supplemental data

Journal Articles

Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

Blood Neoplasia (2024) 1 (3): 100025.

https://doi.org/10.1016/j.bneo.2024.100025

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system

Jun Y. Jiang, Chijioke Nze, Danielle Guffey, Rockbum Kim, Abiodun O. Oluyomi, Omar Rosales, Raka Bandyo, Courtney N. Miller-Chism, Mark M. Udden, Martha P. Mims, Hilary Ma, Gustavo A. Rivero, Akiva Diamond, Purnima S. Teegavarapu, Ang Li, Christopher R. Flowers

Blood Neoplasia (2024) 1 (3): 100020.

https://doi.org/10.1016/j.bneo.2024.100020

Published: 2024

Includes: Supplemental data

Journal Articles

Optimal number of cycles of bendamustine as initial chemoimmunotherapy for older patients with follicular lymphoma

Christopher S. Strouse, Vanessa E. Siebert, Bradley T. Loeffler, Bradley D. McDowell, Brian J. Smith, Brian K. Link

Blood Neoplasia (2024) 1 (3): 100019.

https://doi.org/10.1016/j.bneo.2024.100019

Published: 2024

Includes: Supplemental data

Journal Articles

The landscape of rare genetic variants in familial Waldenström macroglobulinemia

Alexander Pemov, Jung Kim, Wen Luo, Jia Liu, Cole Graham, Kristine Jones, Delphine DeMangel, Neal D. Freedman, Charles Dumontet, Bin Zhu, Mary L. McMaster, Douglas R. Stewart

Blood Neoplasia (2024) 1 (2): 100013.

https://doi.org/10.1016/j.bneo.2024.100013

Published: 2024

Includes: Supplemental data

Journal Articles

Central role of the mTORC1 pathway in glucocorticoid activity against B-ALL cells

Hiroshi Imanaga, Yuichiro Semba, Kensuke Sasaki, Kiyoko Setoguchi, Hillary Maniriho, Takuji Yamauchi, Tatsuya Terasaki, Shigeki Hirabayashi, Fumihiko Nakao, Jumpei Nogami, Shai Izraeli, Koichi Akashi, Takahiro Maeda

Blood Neoplasia (2024) 1 (2): 100015.

https://doi.org/10.1016/j.bneo.2024.100015

Published: 2024

Includes: Supplemental data

Journal Articles

Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma

Wen-Kai Weng, Chaitanya Iragavarapu, Gavin M. Weng, Richard T. Hoppe, Susan Hiniker, Michael S. Khodadoust, Youn H. Kim

Blood Neoplasia (2024) 1 (2): 100007.

https://doi.org/10.1016/j.bneo.2024.100007

Published: 2024

Includes: Supplemental data

Journal Articles

Frequent response monitoring in chronic lymphocytic leukemia clinical trials: what is the value?

Agnes Mattsson, Jeanette Lundin, Tom A. Mulder, Sandra E. Sylvan, Marzia Palma, Lotta Hansson, Anders Österborg

Blood Neoplasia (2024) 1 (2): 100006.

https://doi.org/10.1016/j.bneo.2024.100006

Published: 2024

Journal Articles

Multiple myeloma–associated DIS3 gene is essential for hematopoiesis, but loss of DIS3 is insufficient for myelomagenesis

Hiroto Ohguchi, Yasuyo Ohguchi, Sho Kubota, Kan Etoh, Ai Hamashima, Shingo Usuki, Takako Yokomizo-Nakano, Jie Bai, Takeshi Masuda, Yawara Kawano, Takeshi Harada, Mitsuyoshi Nakao, Takashi Minami, Teru Hideshima, Kimi Araki, Goro Sashida

Blood Neoplasia (2024) 1 (1): 100005.

https://doi.org/10.1016/j.bneo.2024.100005

Published: 2024

Includes: Supplemental data

NARROW

CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas

BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis

COVID-19 vaccination in patients with classic and variant hairy cell leukemia

Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy

Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma

Clinical and pathological features of pediatric peripheral T-cell lymphoma after solid organ transplantation

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

JAK1/2 Inhibitor Ruxolitinib for the Treatment of Systemic Chronic Active Epstein-Barr Virus Disease: A Phase II Study

T-cell lymphoblastic lymphoma compared with T-cell acute lymphoblastic leukemia: similar subtypes and different fusions

Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice

Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study

Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation

Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system

Optimal number of cycles of bendamustine as initial chemoimmunotherapy for older patients with follicular lymphoma

The landscape of rare genetic variants in familial Waldenström macroglobulinemia

Central role of the mTORC1 pathway in glucocorticoid activity against B-ALL cells

Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma

Frequent response monitoring in chronic lymphocytic leukemia clinical trials: what is the value?

Multiple myeloma–associated DIS3 gene is essential for hematopoiesis, but loss of DIS3 is insufficient for myelomagenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only